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Infectious mononucleosis is primarily caused by Epstein-Barr virus (EBV) and is a common di-
agnosis made in emergency departments worldwide. Subclinical and transient transaminase 
ele-vations are a well-established sequela of EBV. However, acute cholestatic hepatitis is a rare 
complication. EBV infection should be considered as part of the differential diagnosis in patients with 
an obstructive pattern on liver function tests without evidence of biliary obstruction demon-strated on 
advanced imaging. [Clin Pract Cases Emerg Med. 2020;X(X):X–X.]
INTRODUCTION
Epstein-Barr virus (EBV) is a DNA virus that causes 
infectious mononucleosis. Infections are common in 
childhood and young adulthood but are usually asymptomatic. 
The classic triad of fever, tonsillitis, and lymphadenopathy 
that frequently presents to the emergency department (ED) is 
more common in adolescents and adults. Elevations in liver 
transaminases are not uncommon with EBV infection, but are 
usually transient and rarely progress to fulminant hepatitis.1,2  
However, significant cholestasis and jaundice are rare 
complications with an incidence of less than 5%.3,4,5 
CASE REPORT
A 23-year-old previously healthy male presented to the 
ED with complaints of a headache that was gradual in onset 
and had been present for the prior 24 hours. He noted some 
lightheadedness and dizziness while standing, which prompted 
him to present to the ED for evaluation. He was febrile to 
100.5 degrees Fahrenheit (F) and tachycardic to 110 beats per 
minute (bpm). The remainder of his physical exam was grossly 
unremarkable with no meningeal signs or focal neurologic 
deficits. He was provided antipyretics and intravenous (IV) 
fluids with complete resolution of his symptoms and discharged 
home with a diagnosis of viral syndrome.  
Two days later, he returned to the ED with complaints 
of continued headache and fever. He recalled a “dry, tickling 
throat,” which was brief and self-limited in the prior two days. 
He was tachycardic, but afebrile on exam. With the exception 
of his tachycardia, his physical exam was again unremarkable 
without an identifiable infectious source. Laboratory 
Naval Medical Center San Diego, Department of Emergency Medicine, San Diego, California
evaluation demonstrated a bandemia of 8% (reference 
range 0-5) as well as mild transaminitis with alanine 
aminotransferase (ALT) 177 units per liter (U/L) (reference 
range 17-63) and aspartate aminotransferase (AST) 171 U/L 
(reference range 12-39). His rapid heterophile antibody test 
was positive. He was discharged home with precautions to 
avoid contact sports and to have repeated liver function tests 
performed by his primary care provider.  
Three days after his second ED visit, he returned with 
jaundice, dark urine, and with continued fever and fatigue. 
He denied sore throat, cough, chest pain, abdominal pain, 
vomiting, diarrhea, hematuria, dysuria, or rash.  He was again 
febrile with a temperature of 100.9° F and a pulse rate of 109 
bpm. There was noticeable scleral icterus and diffuse jaundice. 
He was also noted to have multiple, palpable, posterior 
cervical lymph nodes.  
Laboratory evaluation was notable for a leukocytosis 
of 14.8 x10^3 cells per microliter (mcL) (reference 
4.0-10.5) with lymphocytic predominance of 24% and 
thrombocytopenia of 99x10^3 cells/mcL (reference range 
150-450). Comprehensive metabolic panel was notable 
for mild hyponatremia of 133 millimoles (mmol) per L 
(reference range 136-145 mmol/L), total bilirubin of 7.93 
milligrams per deciliter (mg/dL) (reference 0.15-1.00), direct 
bilirubin of 6.9 mg/dL (reference range <0.2-0.3), alkaline 
phosphatase of 198 U/L (reference range 40-129), ALT of 753 
U/L (reference range 17-63), and AST 692 U/L (reference 
range 12-39). Coagulation studies were within normal limits. 
Acetaminophen level was negative at <1.5 micrograms per 
milliliter (reference range 10-30). Hepatitis serologies were 
Clinical Practice and Cases in Emergency Medicine 2 Articles in Press
Epstein-Barr Virus-induced Jaundice Herold et al.
CPC-EM Capsule
What do we already know about this clinical 
entity? 
Infectious mononucleosis is primarily caused
by Epstein-Barr virus and is a common
diagnosis in the emergency department.
What makes this presentation of disease 
reportable? 
Cholestatic hepatitis is a rare presentation of
Epstein-Barr virus with only approximately
5% of patients presenting with jaundice.
What is the major learning point? 
As emergency providers, it is important that
our differential diagnoses include Epstein-Barr 
virus when evaluating patients with cholestasis.
How might this improve emergency 
medicine practice? 
Keeping Epstein-Barr virus on the 
differential as a cause of cholestatic hepatitis 
may save money on further diagnostic 
imaging and work up.
notable for a reactive hepatitis B virus core antibody, non-
reactive hepatitis B core antibody IgM, positive hepatitis B 
surface antibody, and negative hepatitis B surface antigen 
consistent with immunity due to natural infection. Hepatitis C 
antibody was non-reactive. Human immunodeficiency virus 
testing was negative. Blood cultures were also negative.  EBV 
heterophile antibodies were positive.  
A formal right upper quadrant ultrasound demonstrated 
a mildly enlarged liver with normal contour.  The gallbladder 
was visualized and noted to be contracted. The gallbladder 
wall was noted to be mildly thickened with a measurement of 
0.34 centimeters. There was no evidence of cholelithiasis.  
The patient was admitted to the hospital for supportive 
care and further laboratory evaluation. He was provided IV 
fluids, and liver function tests were trended every six hours. 
Liver enzymes gradually decreased and his jaundice resolved. 
His thrombocytopenia was thought to be related to acute 
hepatitis. Coagulation studies remained within normal limits. 
He was discharged from the hospital with a diagnosis of 
cholestatic hepatitis secondary to EBV. He followed up with 
internal medicine and had serial liver function tests over the 
subsequent weeks.
DISCUSSION
EBV is a member of the herpes virus family and has a 
seroprevalence of 90-95% worldwide.6 EBV is the primary 
cause of infectious mononucleosis, which can occur at all ages 
but is most common during adolescence and early adulthood.7,8 
The likelihood of symptomatic disease is higher in older 
populations, and the risk of severe symptoms is positively 
correlated with age.7 Classic clinical symptoms of infectious 
mononucleosis include a triad of fever, pharyngitis, and 
adenopathy, which usually manifest after an incubation period 
of four to seven weeks.3,7 EBV is transmitted through saliva 
and infiltrates epithelial cells and resting B-cells, replicating 
and spreading throughout the body.9 After its incubation period, 
activation of cytotoxic T lymphocytes and natural killer cells 
occurs, leading to a cell-mediated immune response.7,10 Most 
infections are self-limited with an overall excellent prognosis; 
however, in some cases EBV infection complications can 
range from mild hepatitis to lymphoproliferative disorders, 
hepatosplenomegaly and, rarely, acute liver failure.8  
The diagnosis of EBV is made based on clinical presentation 
and laboratory findings. Clinical presentation may include the 
classic triad of symptoms as well as tonsillar exudates, palatal 
petechiae, hepatosplenomegaly, and hepatitis.9,11 About 5-10% 
may present with jaundice.7 Laboratory analysis may demonstrate 
an absolute lymphocytosis in which more than 10% of the cells 
are atypical and positive heterophile antibody titers. Heterophile 
antibody titers may be falsely negative in the first week and may 
be consistently negative in approximately 10% of patients. If 
this is the case, EBV viral capsid antigen IgG and IgM antibody 
tests as well as EBV nuclear antigen antibodies may be helpful in 
distinguishing the infection.7,8  Serum aminotransferase levels are 
usually elevated by less than five times the upper limit of normal 
and rarely reach over 1000 U/L.
Liver tissue injury is common in EBV infection 
with about 75% of patients exhibiting an increase in 
aminotransferases.7 Cholestatic hepatitis is a rare sequelae of 
EBV, and jaundice is seldom reported; however, it is more 
frequent in people aged 35 and older.12,13,14 If seen, jaundice 
may be due to autoimmune hemolytic anemia, cholestasis 
due to acalculous cholecystitis, biliary duct obstruction due to 
abdominal lymphadenopathy, or cholestatic hepatitis.9,15 The 
pathogenesis of cholestatic hepatitis due to EBV is unclear.  
EBV unlikely infects hepatocytes, biliary epithelium or 
vascular endothelium.3 It has been considered that cholestasis 
may be related to lipid peroxidation and consequent free 
radical production.9,12  
Once the diagnosis of EBV is made, further workup is 
generally not warranted.1,2 Treatment of uncomplicated infectious 
mononucleosis usually requires only symptomatic treatment with 
antipyretics, hydration, and rest.1,2,6 Often patients may experience 
abdominal pain, which may in part be due to splenomegaly.6 If 
splenomegaly is present, it is prudent to warn the patient against 
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physical activity to prevent splenic rupture; although rare, it 
has an incidence of 0.1-0.2%.10 Rare complications of EBV 
may include upper airway obstruction, peritonsillar abscess, 
encephalitis, myocarditis, or pleural effusion.8,9,10 The patient in 
this case recovered without serious intervention.
CONCLUSION
EBV infection has a high prevalence throughout the 
world. Although EBV often leads to self-limited infectious 
mononucleosis, it should be considered in the diagnosis of 
cholestatic hepatitis even in the absence of typical infectious 
mononucleosis clinical signs. It is important for emergency 
care providers to expand their differential to include EBV when 
working up a patient with cholestasis. Heterophile antibody 
testing is widely available and quick to perform and may be 
useful for rapid indication of EBV hepatitis. Providers should 
consider the diagnosis of EBV in all patients with unexplained 
hepatitis regardless of their age or symptomatology. 
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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